X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $3.31 to $3.52
• 50-Day Range: $2.71 to $8.13
• 52-Week Range: $2.67 to $33.90
• Volume: 119,955 shs
• Average Volume: 100,693 shs
• Market Capitalization: $19.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $72.33
• Consensus Rating: Buy

X4 Pharmaceuticals Stock Analysis - MarketRank™

X4 Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 127th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

X4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

X4 Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of X4 Pharmaceuticals is -37.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of X4 Pharmaceuticals is -37.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

X4 Pharmaceuticals has a P/B Ratio of 10.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.09% of the float of X4 Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in X4 Pharmaceuticals has recently increased by 7.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

X4 Pharmaceuticals does not currently pay a dividend.

Dividend Growth

X4 Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

8.09% of the float of X4 Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in X4 Pharmaceuticals has recently increased by 7.43%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

X4 Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for X4 Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for XFOR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, X4 Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,559.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.37% of the stock of X4 Pharmaceuticals is held by insiders.

Percentage Held by Institutions

72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XFOR Stock Analysis - Frequently Asked Questions

How have XFOR shares performed this year?

X4 Pharmaceuticals' stock was trading at $22.0080 at the beginning of the year. Since then, XFOR shares have decreased by 84.7% and is now trading at $3.37.
View the best growth stocks for 2025 here.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) posted its quarterly earnings results on Thursday, May, 1st. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($4.13) by $4.17. The company earned $28.81 million during the quarter, compared to the consensus estimate of $7.03 million.
Read the conference call transcript.

When did X4 Pharmaceuticals' stock split?

X4 Pharmaceuticals shares reverse split before market open on Monday, April 28th 2025. The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' top institutional investors include Kingdon Capital Management L.L.C. (120.92%), Pale Fire Capital SE (35.16%), Charles Schwab Investment Management Inc. (8.32%) and Goldman Sachs Group Inc. (4.73%). Insiders that own company stock include Paula Ragan, Mark Baldry, Mary Dibiase, Arthur Taveras, Tuvia Barlev, Murray Stewart, Michael S Wyzga, Israel Niv and Adam S Mostafa.
View institutional ownership trends.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Intel (INTC).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 6/01/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XFOR
• CIK: 1501697
• Web: www.x4pharma.com
• Phone: (857) 529-8300
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $72.33
• High Stock Price Target: $120.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +2,046.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.14
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$101.17 million
• Net Margins: N/A
• Pretax Margin: -1,484.77%
• Return on Equity: -236.19%
• Return on Assets: -75.14%

Debt

• Debt-to-Equity Ratio: 1.26
• Current Ratio: 4.89
• Quick Ratio: 4.80

Sales & Book Value

• Annual Sales: $31.36 million
• Price / Sales: 0.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 10.87

Miscellaneous

• Outstanding Shares: 5,789,000
• Free Float: 167,783,000
• Market Cap: $19.51 million
• Optionable: Optionable
• Beta: 0.73